| # | Country | Total Patents | |
|---|---|---|---|
| #1 | Australia | 4 | |
| #2 | Brazil | 4 | |
| #3 | China | 4 | |
| #4 | WIPO (World Intellectual Property Organization) | 4 | |
| #5 | Canada | 3 | |
| #6 | EPO (European Patent Office) | 3 | |
| #7 | Republic of Korea | 3 | |
| #8 | United States | 3 | |
| #9 | Israel | 2 | |
| #10 | Mexico | 2 | |
| #11 | Hong Kong | 1 | |
| #12 | Singapore | 1 | |
| #13 | Taiwan | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Organic fine chemistry | |
| #3 | Biotechnology | |
| #4 | Measurement | |
| #5 | Environmental technology |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Medical preparations | |
| #3 | Heterocyclic compounds | |
| #4 | Peptides | |
| #5 | Microorganisms | |
| #6 | Analysing materials | |
| #7 | Climate change adaptation technologies |
| # | Name | Total Patents |
|---|---|---|
| #1 | Chen Shuhui | 19 |
| #2 | Wu Chengde | 8 |
| #3 | Gong Zhen | 8 |
| #4 | Li Jian | 8 |
| #5 | Mao Qinghua | 8 |
| #6 | Huang Yong | 8 |
| #7 | Ding Charles Z | 8 |
| #8 | Hu Lihong | 7 |
| #9 | Xu Zhaobing | 7 |
| #10 | Li Jing | 7 |
| Publication | Filing date | Title |
|---|---|---|
| WO2019238088A1 | Salt form and crystal form of pyridopyridone derivative | |
| CN110305215A | Novel anti-lag-3 antibody polypeptides | |
| CN111542520A | As A2AFused ring derivatives of receptor inhibitors | |
| KR20200015787A | Coumarin ring-based compounds as MEK inhibitors and uses thereof | |
| BR112019014152A2 | HDAC6 SELECTIVE INHIBITORS, METHOD OF PREPARATION FOR THE SAME, AND APPLICATION OF THE SAME | |
| BR112019012176A2 | pharmaceutically acceptable salt or isomer thereof, use thereof and pharmaceutical composition | |
| AU2016423559A1 | The novel monoclonal antibodies to programmed death 1 (PD-1) |